Regeneron Pharmaceuticals Q1 2023 Earnings Preview
Regeneron Pharmaceuticals (NASDAQ:REGN) is scheduled to announce Q1 earnings results on Thursday, May 4th, before market open.
The consensus EPS Estimate is $9.56 (-16.8% Y/Y) and the consensus Revenue Estimate is $3B (+1.0% Y/Y).
Over the last 2 years, REGN has beaten EPS estimates 100% of the time and has beaten revenue estimates 88% of the time.
Over the last 3 months, EPS estimates have seen 3 upward revisions and 7 downward. Revenue estimates have seen 7 upward revisions  and 3 downward.